When the Natural becomes the UN Natural

Save
5 years ago
58

Six-Letter DNA Alphabet Produces Proteins in Cells
Transcription and translation of DNA containing synthetic base pairs becomes a reality in living cells.
In all forms of life on earth, genetic information is composed of a four-letter alphabet—the nucleotides G, C, A, and T, which form the base pairs G-C and A-T. But three years ago, chemistry professor Floyd Romesberg of the Scripps Research Institute in California and colleagues extended this alphabet, reporting the creation of additional artificial nucleotides, X and Y, that could pair up within DNA and take part in replication within a living bacterial cell.
https://www.the-scientist.com/news-opinion/six-letter-dna-alphabet-produces-proteins-in-cells-30572

A Semi-Synthetic Organism that Stores and Retrieves Increased Genetic Information
Since at least the last common ancestor of all life on earth, genetic information has been stored in a four-letter alphabet that is propagated and retrieved by the formation of two base pairs. The central goal of synthetic biology is to create new life forms and functions1, and the most general route to this goal is the creation of semi-synthetic organisms (SSOs) whose DNA harbors two additional letters that form a third, unnatural base pair (UBP)....
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796663/

Synthorx bought by Sanofi
https://www.cnbc.com/2019/12/09/frances-sanofi-to-buy-biotech-firm-synthorx-for-2point5-billion.html?fbclid=IwAR0pgXBX-lUfGqQ75UmjBR7vkKnDk8CkJ4BkRglVsDn7XQUIpLFEwfcZjsQ
https://www.sandiegouniontribune.com/business/story/2019-12-09/mega-deal-la-jolla-startup-synthorx-sells-for-2-5-billion-to-sanofi

Sanofi and GSK
Sanofi is developing the antigen (the protein that stimulates the body’s immune response against the virus), which is based on recombinant DNA technology. “We are using an existing technology that was designed for influenza, and we’re applying it to the new virus that causes COVID-19 disease,” said John Shiver, Head of Sanofi Vaccine R&D. “Having the existing platform and partnerships are key to finding the optimal vaccine that we hope can both have impact against disease while contributing to vast and urgent global demand.”
And GSK is contributing an adjuvant, an ingredient added to enhance the immune response, which reduces the amount of vaccine protein required per dose and improves the chances of delivering an effective vaccine that can be manufactured at scale.
Sanofi is also exploring a second COVID-19 vaccine candidate, in partnership with Translate Bio, a clinical-stage messenger RNA (mRNA) biotechnology company. The project is on track to start clinical trials by December.
https://www.sanofi.com/en/about-us/our-stories/sanofi-s-response-in-the-fight-against-covid-19

https://www.statnews.com/2020/09/03/sanofi-gsk-covid19-vaccine-human-trials/

XNA
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756832/

Thanks to Franzetta for the artwork!
http://www.vaccinefraud.com/franzetta.html

you can find Patrick's book Prion Agenda here:
http://www.vaccinefraud.com/books.html

demon or diseases?
https://youtu.be/sL5IL8kOn0s?t=3034

Loading 1 comment...